Søren Kragh Moestrup

CD163 and inflammation: Biological, diagnostic and therapeutic aspects

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

CD163 and inflammation : Biological, diagnostic and therapeutic aspects. / Etzerodt, Anders; Moestrup, Søren Kragh.

In: Antioxidants & Redox Signaling, Vol. 18, No. 17, 2013, p. 2352-2363.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Etzerodt, Anders ; Moestrup, Søren Kragh. / CD163 and inflammation : Biological, diagnostic and therapeutic aspects. In: Antioxidants & Redox Signaling. 2013 ; Vol. 18, No. 17. pp. 2352-2363.

Bibtex

@article{4bbc99cd7d9845a8bb2942ca1ad204da,
title = "CD163 and inflammation: Biological, diagnostic and therapeutic aspects",
abstract = "Significance: The hemoglobin scavenger receptor CD163 is a macrophage-specific protein and the upregulated expression of this receptor is one of the major changes in the macrophage switch to alternative activated phenotypes in inflammation. Accordingly, a high CD163 expression in macrophages is a characteristic of tissues responding to inflammation. The scavenging of the oxidative and pro-inflammatory hemoglobin leading to stimulation of the heme-oxygenase-1 and production of anti-inflammatory heme metabolites indicate that CD163 thereby indirectly contributes to the anti-inflammatory response. Recent Advances: In addition to this biological role in inflammation CD163 is a potential inflammation biomarker and a therapeutic target. The biomarker form of CD163 is the soluble plasma CD163 that arise from the increased shedding of CD163 mediated by the tumor necrosis factor-α (TNFα) cleaving enzyme. This explains that a steadily increasing literature documents that the plasma level of soluble CD163 is increased in a large spectrum of acute and chronic inflammatory disorders. The non-shed membrane form of CD163 in macrophages constitutes a target for drugs to be directed to macrophages in inflammation. This approach has been used in an animal inflammation model to highly increase the apparent therapeutic index of anti-inflammatory glucocorticoid drug that was coupled to an anti-CD163 antibody. Furthermore, other recent animal data, which indirectly involve CD163 in macrophages, demonstrate that injections of haptoglobin attenuate hemoglobin-induced damages after blood transfusion. Critical issues and future directions The diagnostic and therapeutic properties of CD163 await further clinical studies and regulatory approval before implementation in the clinic.",
author = "Anders Etzerodt and Moestrup, {S{\o}ren Kragh}",
year = "2013",
doi = "10.1089/ars.2012.4834",
language = "English",
volume = "18",
pages = "2352--2363",
journal = "Antioxidants & Redox Signaling",
issn = "1523-0864",
publisher = "Mary AnnLiebert, Inc. Publishers",
number = "17",

}

RIS

TY - JOUR

T1 - CD163 and inflammation

T2 - Biological, diagnostic and therapeutic aspects

AU - Etzerodt, Anders

AU - Moestrup, Søren Kragh

PY - 2013

Y1 - 2013

N2 - Significance: The hemoglobin scavenger receptor CD163 is a macrophage-specific protein and the upregulated expression of this receptor is one of the major changes in the macrophage switch to alternative activated phenotypes in inflammation. Accordingly, a high CD163 expression in macrophages is a characteristic of tissues responding to inflammation. The scavenging of the oxidative and pro-inflammatory hemoglobin leading to stimulation of the heme-oxygenase-1 and production of anti-inflammatory heme metabolites indicate that CD163 thereby indirectly contributes to the anti-inflammatory response. Recent Advances: In addition to this biological role in inflammation CD163 is a potential inflammation biomarker and a therapeutic target. The biomarker form of CD163 is the soluble plasma CD163 that arise from the increased shedding of CD163 mediated by the tumor necrosis factor-α (TNFα) cleaving enzyme. This explains that a steadily increasing literature documents that the plasma level of soluble CD163 is increased in a large spectrum of acute and chronic inflammatory disorders. The non-shed membrane form of CD163 in macrophages constitutes a target for drugs to be directed to macrophages in inflammation. This approach has been used in an animal inflammation model to highly increase the apparent therapeutic index of anti-inflammatory glucocorticoid drug that was coupled to an anti-CD163 antibody. Furthermore, other recent animal data, which indirectly involve CD163 in macrophages, demonstrate that injections of haptoglobin attenuate hemoglobin-induced damages after blood transfusion. Critical issues and future directions The diagnostic and therapeutic properties of CD163 await further clinical studies and regulatory approval before implementation in the clinic.

AB - Significance: The hemoglobin scavenger receptor CD163 is a macrophage-specific protein and the upregulated expression of this receptor is one of the major changes in the macrophage switch to alternative activated phenotypes in inflammation. Accordingly, a high CD163 expression in macrophages is a characteristic of tissues responding to inflammation. The scavenging of the oxidative and pro-inflammatory hemoglobin leading to stimulation of the heme-oxygenase-1 and production of anti-inflammatory heme metabolites indicate that CD163 thereby indirectly contributes to the anti-inflammatory response. Recent Advances: In addition to this biological role in inflammation CD163 is a potential inflammation biomarker and a therapeutic target. The biomarker form of CD163 is the soluble plasma CD163 that arise from the increased shedding of CD163 mediated by the tumor necrosis factor-α (TNFα) cleaving enzyme. This explains that a steadily increasing literature documents that the plasma level of soluble CD163 is increased in a large spectrum of acute and chronic inflammatory disorders. The non-shed membrane form of CD163 in macrophages constitutes a target for drugs to be directed to macrophages in inflammation. This approach has been used in an animal inflammation model to highly increase the apparent therapeutic index of anti-inflammatory glucocorticoid drug that was coupled to an anti-CD163 antibody. Furthermore, other recent animal data, which indirectly involve CD163 in macrophages, demonstrate that injections of haptoglobin attenuate hemoglobin-induced damages after blood transfusion. Critical issues and future directions The diagnostic and therapeutic properties of CD163 await further clinical studies and regulatory approval before implementation in the clinic.

U2 - 10.1089/ars.2012.4834

DO - 10.1089/ars.2012.4834

M3 - Journal article

C2 - 22900885

VL - 18

SP - 2352

EP - 2363

JO - Antioxidants & Redox Signaling

JF - Antioxidants & Redox Signaling

SN - 1523-0864

IS - 17

ER -